— ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported Q4 2019 loss of $0.34 per share, vs. $0.36 expected.
— Revenue grew 65% to $98.3 million vs. $97.76 million expected.
— For FY20, NUPLAZID sales is expected to be between $440 million and $470 million.
— For fiscal 2020, GAAP R&D expense is expected to be between $270 and $285 million and GAAP SG&A expense is expected to be between $440 and $460 million.
— ACAD shares rose about 4% following the earnings announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event
Most Popular
Docusign (DOCU) Earnings: 3Q26 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported its earnings results for the third quarter of 2026. Revenue increased 8% year-over-year to $818.4 million. GAAP net income was $83.7 million, or $0.40
Infographic: How Ulta Beauty (ULTA) performed in Q3 2025
Ulta Beauty, Inc. (NASDAQ: ULTA) reported its earnings results for the third quarter of 2025. Net sales increased 12.9% year-over-year to $2.9 billion, driven by comparable sales growth, the Space
Hewlett Packard Enterprise (HPE) Earnings: 4Q25 Key Numbers
Hewlett Packard Enterprise (NYSE: HPE) reported revenue of $9.7 billion for the fourth quarter of 2025, up 14% from the prior-year period in actual dollars and in constant currency. Net
